Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.460
-0.360 (-12.77%)
At close: Jan 28, 2026, 4:00 PM EST
2.490
+0.030 (1.22%)
After-hours: Jan 28, 2026, 4:53 PM EST
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$406,571
Profits / Employee
-$1,308,000
Market Cap
19.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 7 | -11 | -61.11% | 6 | 1 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Dec 31, 2022 | 17 | 2 | 13.33% | 16 | 1 |
| Dec 31, 2021 | 15 | 3 | 25.00% | 14 | 1 |
| Dec 31, 2020 | 12 | -7 | -36.84% | 11 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| BioAtla | 61 |
| Lunai Bioworks | 29 |
| VYNE Therapeutics | 13 |
| Iterum Therapeutics | 9 |
| ProMIS Neurosciences | 8 |
| Allarity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
TRAW News
- 15 days ago - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewsWire
- 3 months ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 3 months ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 3 months ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 5 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 5 months ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 6 months ago - Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire